viewCellmid Limited

Cellmid expanding products, portfolio and markets; and approaching profitablity

Cellmid Limited (ASX:CDY) CEO Maria Halasz speaks to Proactive Investors about the company's diversified and global operations, and recent cash raise.

"We are fully funded are really ready to make this company a profitable entity. So the majority of the funding we really raised for our consumer health business. We have so many opportunities now in all the the different geographical regions, and we really want to put product through, make sure that we can support that growth," says Halasz.

In addition to notable advancements in the consumer health business, Cellmid has been progressing its global portfolio of intellectual property relating to midkine (MK) research, convening the 5th Midkine Symposium in Munich, Germany in May.

Halasz explains, "Midkine is a protein that we all have... It really only appears in the body in adults as part of the pathogenesis of certain diseases, and therefore it is an important disease target. We at Cellmid hold literally all the intellectual property globally around this new target for disease management and treatment, and so this is a very exciting area."

Quick facts: Cellmid Limited

Price: 0.099 AUD

Market: ASX
Market Cap: $9.56 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...



Cellmid is a well funded life sciences company that see a path to profitability

Cellmid (ASX:CDY) Chief Executive and Managing Director Maria Halasz sat down with Christine Corrado from Proactive Investors New York to discuss their biotech company that now has products available in the United States. Halasz telling Proactive they are about to spin out into 2...

on 05/15/2019

2 min read